SCHEMBL264867

SCHEMBL264867

C/C=C\C(=O)OCC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL182296 1.00
SCHEMBL24483 1.00
Water SCHEMBL27877032 0.97
Fluoride SCHEMBL28181807 0.97
SCHEMBL29961400 0.97
Bromide SCHEMBL5073248 0.97
Bromide SCHEMBL5073250 0.97
Methylamine SCHEMBL11681719 0.95 HCAR2 (0.58)
Alcohol SCHEMBL16053498 0.95 HCAR2 (0.58)
Methylamine SCHEMBL28259823 0.95 HCAR2 (0.58)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230182462-A1 METHOD FOR COMPOSITE DELAMINATION GRST INTERNATIONAL LIMITED (CN) 2023-06-15 US claimed
US-20230136670-A1 METHOD FOR COMPOSITE DELAMINATION GRST SINGAPORE PTE. LTD. (SG) 2023-05-04 US claimed
US-20250380732-A1 AEROSOLISABLE FORMULATION NICOVENTURES TRADING LTD (GB) 2025-12-18 US disclosed
US-20250241356-A1 ORAL COMPOSITION COMPRISING RECEPTOR MODULATOR DANIEL MICHAEL S (US) 2025-07-31 US disclosed
US-20250205167-A1 NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME SAIL BIOMEDICINES, INC. 2025-06-26 US disclosed
CN-119955196-A Food packaging box based on polyethylene plastic and production method thereof 东莞市瑞翔包装制品有限公司 2025-05-09 CN disclosed
EP-4543230-A1 AEROSOLISABLE FORMULATION Nicoventures Trading Limited (GB) 2025-04-30 EP disclosed
EP-4543229-A1 ORAL COMPOSITION COMPRISING A RECEPTOR MODULATOR Nicoventures Trading Limited (GB) 2025-04-30 EP disclosed
EP-4499607-A1 NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME Sail Biomedicines, Inc. (US) 2025-02-05 EP disclosed
CN-119072464-A Novel ionizable lipids and lipid nanoparticles and methods of use thereof 赛欧生物医药股份有限公司 2024-12-03 CN disclosed
WO-2023247962-A1 AEROSOLISABLE FORMULATION Nicoventures Trading Limited (GB) 2023-12-28 WO disclosed
US-20110269994-A1 METHOD OF PRODUCING A TRIARYLAMINE COMPOUND FUJIFILM CORPORATION (JP) 2011-11-03 US disclosed
EP-1954274-B1 SUBSTITUTED QUINOLONES AND METHODS OF USE CHEMOCENTRYX INC (US) 2010-11-03 EP disclosed
US-20100248390-A1 COMPOSITIONS AND METHODS FOR IDENTIFYING LIGANDS OF ODORANT RECEPTORS DUKE UNIVERSITY (US) 2010-09-30 US disclosed
US-20090197834-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-08-06 US disclosed
US-7393985-B2 Supported ruthenium nanoparticle catalyst for cis -dihydroxylation and oxidative cleavage of alkenes THE UNIVERSITY OF HONG KONG (CN) 2008-07-01 US disclosed
US-7354946-B2 prominent growth inhibitory activity against tumor cells; cyclin dependent kinase inhibitors; colon cancer; N'-(3-t-butylisoindolino[3,2-b]oxazolidin-4-on-8-yl)-N-(4-(N-benzylpyrrolidin-3-yl)pyridin-2-yl)urea BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-04-08 US disclosed
US-7354946-B2 prominent growth inhibitory activity against tumor cells; cyclin dependent kinase inhibitors; colon cancer; N'-(3-t-butylisoindolino[3,2-b]oxazolidin-4-on-8-yl)-N-(4-(N-benzylpyrrolidin-3-yl)pyridin-2-yl)urea BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-04-08 US disclosed
US-20070027147-A1 Biarylurea derivatives MSD K.K. (JP) 2007-02-01 US disclosed
US-20070027147-A1 Biarylurea derivatives MSD K.K. (JP) 2007-02-01 US disclosed